Key Highlights

● ARWR shares closed down 12.40% at $70.67, leaving the company's Market Value around $9.98 billion.

● The pullback followed a powerful run to record highs rather than any fresh negative development.

● Plozasiran, the company's lead RNAi candidate, posted positive Phase 3 SHASTA-3 and SHASTA-4 results, including a 78% reduction in acute pancreatitis events versus placebo.

● Fiscal Q3 2026 Revenue was $75.3 million with a net loss of $194.3 million; the company held roughly $1.567 billion in total cash resources.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) stood out in mid-September 2026 trading as the RNAi-focused drug developer posted a sharp, double-digit decline. Shares closed down 12.40% at $70.67, leaving the S&P MidCap 400 biotech stock's market value around $9.98 billion. The size of the move caught attention, particularly because it followed a powerful run to record highs rather than any fresh setback.

The Latest Share-Price Move

The reported drop of about 12.40% marked a pronounced single-day pullback in a stock that had climbed steeply in late August and early September. Large swings are not unusual for Arrowhead, whose shares tend to react strongly to clinical data, regulatory milestones and index events. The decline arrived after the stock had reached record territory, which shapes how the move is best understood.

Recent Company Developments

Arrowhead's recent narrative has been driven by plozasiran. The company reported positive Phase 3 results from its SHASTA-3 and SHASTA-4 studies around the European Society of Cardiology (ESC) Congress, showing median triglyceride reductions of roughly 79% to 81% and a statistically significant 78% reduction in acute pancreatitis events versus placebo. Plozasiran also holds FDA Breakthrough Therapy Designation in severe hypertriglyceridemia, and its commercial form, REDEMPLO, has been launched with prescription volumes roughly doubling in the fiscal third quarter and Marketing authorizations secured in Europe and Australia.

Latest Financial Results

For fiscal 2026's third quarter, ended 30 June 2026 and reported in early August, Arrowhead posted revenue of $75.3 million and a net loss attributable to the company of $194.3 million, or Diluted Earnings per Share of $(1.36). Cash and equivalents stood at $19.7 million, with available-for-sale securities of about $1.547 billion bringing total cash resources to roughly $1.567 billion. The company did not provide formal forward earnings guidance and remains in a commercial-transition phase.

Sector and Market Context

Arrowhead operates in RNAi and genetic-medicine biotechnology, a volatile, catalyst-driven corner of the market where sizable single-day swings around trial data and regulatory decisions are common. The company is shifting from clinical-stage development toward commercialization with plozasiran and REDEMPLO. Broad biotech risk sentiment can amplify moves in names like this, in either direction.

Profit-Taking After a Record Run

The most likely explanation is profit-taking, or a sell-the-news reaction, after a strong catalyst-driven run to record highs, rather than a new negative event. With the positive Phase 3 readout realized and the shares elevated, a double-digit pullback is consistent with investors locking in gains, and broader biotech sentiment may have added to the pressure. Importantly, no confirmed new negative trial result, financing action or regulatory setback was identified for the specific session. Key items ahead include plozasiran's regulatory timelines and potential label breadth, and REDEMPLO's commercial uptake and prescriber growth. Investors may also track additional pipeline readouts, the cash runway given ongoing net losses, and any Partnership or licensing deals. For now, Arrowhead's decline appears to reflect the mechanics of a post-catalyst stock at record highs rather than a change in its clinical or commercial story.